Medicare Part D a boon for drug companies, House report says

Taxpayers pay up to 30% more for prescriptions under the privately administered program than under Medicaid, the House Committee on Oversight and Government Reform finds. U.S. drug manufacturers are reaping a windfall from taxpayers because Medicare's privately administered prescription drug benefit program pays more than other government programs for the same medicines, a House committee charged in a report Thursday.

Read the whole article on LA Times - Science

More from LA Times - Science